CL2022003206A1 - Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) - Google Patents

Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)

Info

Publication number
CL2022003206A1
CL2022003206A1 CL2022003206A CL2022003206A CL2022003206A1 CL 2022003206 A1 CL2022003206 A1 CL 2022003206A1 CL 2022003206 A CL2022003206 A CL 2022003206A CL 2022003206 A CL2022003206 A CL 2022003206A CL 2022003206 A1 CL2022003206 A1 CL 2022003206A1
Authority
CL
Chile
Prior art keywords
quinolone
div
sol
cancer
treatment
Prior art date
Application number
CL2022003206A
Other languages
English (en)
Inventor
Comer Eamon
Duncan Kenneth
Cocozaki Alexis
Campbell John
Harvey Darren
Munchhof Michael
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CL2022003206A1 publication Critical patent/CL2022003206A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente divulgación proporciona nuevos compuestos, composiciones que comprenden los compuestos y métodos de uso de los mismos.
CL2022003206A 2019-03-28 2022-11-17 Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) CL2022003206A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825507P 2019-03-28 2019-03-28
US201962952599P 2019-12-23 2019-12-23

Publications (1)

Publication Number Publication Date
CL2022003206A1 true CL2022003206A1 (es) 2023-07-07

Family

ID=70334131

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021002501A CL2021002501A1 (es) 2019-03-28 2021-09-27 Compuestos novedosos y métodos de uso de los mismos.
CL2022003206A CL2022003206A1 (es) 2019-03-28 2022-11-17 Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021002501A CL2021002501A1 (es) 2019-03-28 2021-09-27 Compuestos novedosos y métodos de uso de los mismos.

Country Status (14)

Country Link
US (1) US20220144812A1 (es)
EP (1) EP3946623A1 (es)
JP (1) JP2022527279A (es)
KR (1) KR20210151849A (es)
CN (1) CN113891749A (es)
AU (1) AU2020244861A1 (es)
BR (1) BR112021019300A2 (es)
CA (1) CA3134826A1 (es)
CL (2) CL2021002501A1 (es)
CO (1) CO2021014351A2 (es)
IL (1) IL286649A (es)
MX (1) MX2021011699A (es)
SG (1) SG11202110591SA (es)
WO (1) WO2020198567A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022138944A1 (ja) * 2020-12-25 2022-06-30 国立研究開発法人国立がん研究センター Ｓｗｉ／ｓｎｆ複合体機能異常がんの合成致死性に基づく治療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109122D0 (en) * 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
CN101370782A (zh) * 2005-12-12 2009-02-18 阿斯利康(瑞典)有限公司 烷基磺酰胺喹啉
JP2009524656A (ja) * 2006-01-27 2009-07-02 アストラゼネカ・アクチエボラーグ アミド置換キノリン
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
CN101289460B (zh) * 2008-06-06 2011-09-14 山东大学 有机硼酸类化合物及其作为荧光探针的应用
ES2622575T3 (es) * 2008-07-10 2017-07-06 General Incorporated Association Pharma Valley Project Supporting Organization Inhibidor de STAT3 que contiene un derivado de quinolincarboxamida como ingrediente activo
KR20180005178A (ko) * 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 치환된 퀴나졸린 화합물 및 이의 사용방법
KR20190040971A (ko) 2016-07-25 2019-04-19 에피자임, 인코포레이티드 Crebbp 관련 암 치료법
CA3034652A1 (en) * 2016-09-26 2018-03-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
LT3555070T (lt) * 2016-12-19 2023-09-11 Epizyme, Inc. Aminu pakeisti heterocikliniai junginiai, kaip ehmt2 inhibitoriai, ir jų panaudojimo būdai

Also Published As

Publication number Publication date
US20220144812A1 (en) 2022-05-12
CN113891749A (zh) 2022-01-04
EP3946623A1 (en) 2022-02-09
CL2021002501A1 (es) 2022-06-17
MX2021011699A (es) 2022-01-18
SG11202110591SA (en) 2021-10-28
WO2020198567A8 (en) 2020-11-19
WO2020198567A1 (en) 2020-10-01
IL286649A (en) 2021-10-31
BR112021019300A2 (pt) 2021-12-14
KR20210151849A (ko) 2021-12-14
CA3134826A1 (en) 2020-10-01
AU2020244861A1 (en) 2021-11-18
CO2021014351A2 (es) 2022-01-17
JP2022527279A (ja) 2022-06-01

Similar Documents

Publication Publication Date Title
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CL2020002405A1 (es) Inhibidores de kras g12c y métodos para su uso (divisional de la solicitud no. 201903394)
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CO2022004595A2 (es) Aminas bicíclicas como inhibidoras de la cdk2
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
UY38476A (es) Inhibidores de arg1 y/o arg2
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CO2022000481A2 (es) Inhibidores de enzimas
CL2021001027A1 (es) Inhibidores selectivos de rgmc y el uso de los mismos
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
CL2021000950A1 (es) Anticuerpos contra el lif y usos de los mismos (divisional de la solicitud no. 201901717)
CL2019002583A1 (es) Inhibidores duales de magl y faah.